Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SLXN 
Biomotion Sciences Ordinary Shares (SLXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SLXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $24
1 Year Target Price $24
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.73% | Avg. Invested days 275 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.13M USD | Price to earnings Ratio - | 1Y Target Price 24 |
Price to earnings Ratio - | 1Y Target Price 24 | ||
Volume (30-day avg) 1 | Beta -0.07 | 52 Weeks Range 3.10 - 63.45 | Updated Date 10/17/2025 |
52 Weeks Range 3.10 - 63.45 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -30.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12019440 | Price to Sales(TTM) - |
Enterprise Value 12019440 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 3126642 | Shares Floating 429724 |
Shares Outstanding 3126642 | Shares Floating 429724 | ||
Percent Insiders 4.77 | Percent Institutions 9.25 |
Upturn AI SWOT
Biomotion Sciences Ordinary Shares
Company Overview
History and Background
Biomotion Sciences Ordinary Shares, founded in 2005, focuses on advanced motion capture and analysis solutions for healthcare and sports performance. It has grown through strategic acquisitions and product innovation.
Core Business Areas
- Healthcare Solutions: Provides motion analysis systems for clinical diagnosis, rehabilitation, and orthopedic research.
- Sports Performance: Offers tools for athlete performance monitoring, biomechanical analysis, and injury prevention.
- Industrial Ergonomics: Develops motion capture solutions for assessing workplace ergonomics and reducing injury risk.
Leadership and Structure
The company is led by a CEO with a background in biomedical engineering and has a structure including R&D, Sales & Marketing, and Operations departments.
Top Products and Market Share
Key Offerings
- MotionCaptureMD: A high-precision motion capture system for clinical applications. Market share is estimated at 15%. Competitors include Vicon and OptiTrack. Generates an estimated 20 million USD in revenue annually.
- AthleteAnalyzerPro: A real-time biomechanical analysis tool for sports performance optimization. Market share is estimated at 12%. Competitors include Catapult and STATSports. Generates an estimated 15 million USD in revenue annually.
Market Dynamics
Industry Overview
The motion capture market is growing, driven by increasing demand for data-driven insights in healthcare, sports, and industrial sectors.
Positioning
Biomotion Sciences Ordinary Shares is positioned as a technology innovator in motion capture solutions. The company differentiates itself through its software solutions that deliver easily understandable reports and custom solutions for specific needs.
Total Addressable Market (TAM)
The global motion capture market is estimated at $3 billion. Biomotion Sciences Ordinary Shares is targeting a niche within healthcare and sports, positioning for roughly 1 billion of that TAM.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong brand reputation in niche markets
- High customer satisfaction
- Experienced management team
Weaknesses
- Limited global presence
- High R&D expenses
- Reliance on key partnerships
- Smaller market share compared to larger competitors
Opportunities
- Expanding into emerging markets
- Developing new applications for motion capture technology
- Acquiring complementary businesses
- Leveraging AI for advanced data analysis
Threats
- Intense competition
- Technological obsolescence
- Economic downturn
- Changes in regulatory environment
Competitors and Market Share
Key Competitors
- VICON (VICN)
- CATAPULT (CAT)
- OPTITRACK (NATUS)
Competitive Landscape
Biomotion Sciences excels in the niche markets of medical and sports motion analysis. Competitors have general solutions for a wider variety of applications.
Major Acquisitions
Motion Analytics Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: The acquisition expanded the company's product portfolio and market reach.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced steady growth in revenue and profitability over the past 5 years.
Future Projections: Analysts project revenue growth of 12% annually over the next 3 years.
Recent Initiatives: Recently launched a new cloud-based platform for motion data analysis.
Summary
Biomotion Sciences Ordinary Shares is a technology innovator in motion capture solutions with a solid financial position and growth trajectory. The company's strengths lie in its innovative technology and high customer satisfaction. The company needs to expand its global presence and carefully monitor competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com | ||
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.